Start-Up Spotlight: BioVentrix Expects Revivent TC Heart Failure Device To Succeed Where Others Failed

Two-year data from a European trial showed BioVentrix’s Revivent TC system significantly reduces left-ventricular volume and improves left-ventricular function in patients with heart failure following a myocardial infarction. The company expects to complete a US pivotal trial of the device in 2021 and launch the device in the US with funding from a planned initial public offering.

Start-up Spotlight

BioVentrix Inc. believes its Revivent TC transcatheter ventricular enhancement system represents a breakthrough in technology for reshaping the left ventricle of a failing heart and is supporting multiple clinical trials to prove that.

Revivent TC is intended for patients with symptomatic heart failure and left-ventricular dilatation caused by myocardial scaring after a myocardial...

More from Clinical Trials

More from R&D